The Week in Review: September 8 – September 15, 2017

Friday, September 15, 2017 News Recap: President’s Report from HepCBC’s Annual General Meeting (AGM) HepCBC held its Annual General Meeting on September 12, 2017, and we are pleased to note that all the issues that we needed to address were covered.  Rosemary Plummer has stepped down as president after 2 GREAT YEARS of service, but the rest of the Board of Directors has been re-elected, and some very important changes to our Constitution and Bylaws ...

How liver cancer develops

An international team of researchers headed up by UZH Professor Achim Weber from the Institute of Pathology and Molecular Pathology of the University Hospital Zurich and Mathias Heikenwälder, professor at the German Cancer Research Center in Heidelberg, Germany, has discovered a major mechanism in the development of liver cancer. One of the main players in this process is enzyme caspase-8, which assumes an important dual role. Liver cancer is the second...

Overview: Innovative treatments target liver cancer

Traditional treatment for liver cancer typically involves surgery, chemotherapy and external beam radiation. However, not all patients are candidates for surgery and some may not respond to traditional chemotherapy and radiation. Today, there are several innovative approaches — such as radioembolization, chemoebolization and microwave ablation — that are making treatment more precise and more accessible to a broader number of patients. With radioemboli

MicroRNA-34a as a Therapeutic Target in HCC

MicroRNA-34a, one of the most documented tumor suppressor microRNAs, is being evaluated as a potential therapeutic target in hepatocellular carcinoma (HCC) in a study being presented at the 2017 International Liver Congress. Results from a study of microRNA-34a and natural killer (NK) cells suggest that microRNA-34a could have a role in regulating cytotoxicity and development of the effector NK cells and their target cells. Lead author Amira Abdelhamid

Independent Prognostic Markers of HCC Recurrence Identified

Higher levels of hepatocytes positive for pERK immunostaining and greater microvascular invasion have emerged as independent prognostic factors of recurrence in patients following sorafenib (Nexavar) treatment for hepatocellular carcinoma (HCC), researchers reported at the 2017 International Liver Congress in Amsterdam. “The is an unmet need for adjuvant treatment for HCC since HCC recurrence after resection or ablation occurs in 70% of patients within 5 y

How new hepatitis C drugs could tackle liver cancer, too

How to cut rates of liver cancer? Reducing hepatitis C rates would be a good start. Wider availability of newer hepatitis C drugs may not only lead to fewer cases of this blood-borne disease, but may also slow the rise in related liver cancer. But these so-called direct acting antiviral drugs have not been widely available in Australia or overseas for long enough for us to confirm this long-term trend. So, we need to see if their increased use is li

High Rates of Hepatocellular Carcinoma After Hepatitis C Treatment

NEW YORK (Reuters Health) - Patients treated with direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV)-related cirrhosis appear to have high rates of hepatocellular carcinoma (HCC) – Will Boggs MD. "If these findings are confirmed from other centers, studies are suggested to examine mechanisms of these findings," Dr. Ashwani Singal from University of Alabama at Birmingham told Reuters Health by email. Some studies have shown unexpectedly h

Doctors’ Notes: Why Toronto is a liver cancer hot spot

Survival rates are rising but more than 1,000 people die every year in Ontario from liver cancer. Liver cancer is to blame for more than a thousand deaths every year in Ontario — and most of these occur in the Greater Toronto Area. In fact, the epidemic level of liver cancer in this city often goes unrecognized, as it’s diluted by provincial and national statistics. So what is it about Toronto that makes it such a hot spot for this type of cancer? M

U.S.: FDA grants priority review to Stivarga for second-line treatment of HCC

The FDA granted priority review to regorafenib tablets as a second-line systemic treatment for patients with hepatocellular carcinoma, according to the drug’s manufacturer. The review is based on results from the international, multicenter, placebo-controlled phase 3 RESORCE trial, in which 573 patients with hepatocellular carcinoma (HCC) who previously had disease progression during treatment with sorafenib (Nexavar, Bayer) were randomly assigned (2:1) t

The Week in Review: Nov 11 – Nov 18, 2016

Friday, November 18, 2016 AASLD, 2016: Focus on Liver Cancer and DAAs This year at The Liver Meeting® — held by the American Association for the Study of Liver Diseases (AASLD 2016) — there were a lot of presentations on Liver Cancer (HCC) and the new DAAs.  Over the past decade, the prevalence of cirrhosis has increased by almost 40 percent among people with hepatitis C (HCV) in the United States. The proportion of hepatitis C patients with cirrhosi...